Literature DB >> 26175944

Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation.

Quan Zhang1, Yan Li2, Tingting Liang1, Xuemian Lu3, Xingkai Liu4, Chi Zhang3, Xin Jiang4, Robert C Martin2, Mingliang Cheng5, Lu Cai6.   

Abstract

Diabetes associated metabolic syndrome has been shown to be an independent risk factor for the development of hepatocellular carcinoma (HCC). Cirrhosis, in fact, was not always a prerequisite of HCC development and this might particularly apply to the metabolic abnormality associated HCC. This study was to investigate diabetes associated HCC and the potential role of FGF21 during carcinogenetic transformation of HCC. Dimethylnitrosamine (DEN) was used to induce HCC in the diabetic OVE26 mice. Pronounced damage characterized by steatohepatitis was found in the liver of diabetic mice. Steatohepatitis accompanied by constant cell proliferation and tumor cell growth were also found in the hepatic tissues of diabetic OVE26 mice when DEN being administrated. FGF21 protein level increased in liver tissues at an early stage along with steatohepatitis in diabetic OVE26 mice, but decreased in liver tissues later when HCC was developed. In addition, decreased FGF21 protein level was associated with cancerous hyper-proliferation and aberrant p53 and TGF-β/Smad signaling during HCC development. Loss of FGF21 may play an important role in HCC carcinogenetic transformation during metabolic liver injury in diabetic animals. The present finding calls attention to the need to control metabolic disorders associated with diabetes and may further develop a protective strategy against HCC.

Entities:  

Keywords:  FGF21; Hepatocellular carcinoma; OVE26 mice; diabetes; dimethylnitrosamine

Year:  2015        PMID: 26175944      PMCID: PMC4497442     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  55 in total

1.  Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells.

Authors:  Yun Lü; Jing-Hua Liu; Li-Ke Zhang; Jie DU; Xiang-Jun Zeng; Gang Hao; Ji Huang; Dong-Hui Zhao; Guo-Zhong Wang; Ying-Chuan Zhang
Journal:  Chin Med J (Engl)       Date:  2010-12       Impact factor: 2.628

Review 2.  Metabolic actions of fibroblast growth factor 21.

Authors:  Daniel Cuevas-Ramos; Carlos A Aguilar-Salinas; Francisco J Gómez-Pérez
Journal:  Curr Opin Pediatr       Date:  2012-08       Impact factor: 2.856

3.  Excess risk of primary liver cancer in patients with diabetes mellitus.

Authors:  H O Adami; W H Chow; O Nyrén; C Berne; M S Linet; A Ekbom; A Wolk; J K McLaughlin; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

4.  Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.

Authors:  M Mraz; M Bartlova; Z Lacinova; D Michalsky; M Kasalicky; D Haluzikova; M Matoulek; I Dostalova; V Humenanska; M Haluzik
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-11       Impact factor: 3.478

5.  Recruitment of histone methyltransferase G9a mediates transcriptional repression of Fgf21 gene by E4BP4 protein.

Authors:  Xin Tong; Deqiang Zhang; Katie Buelow; Anirvan Guha; Blake Arthurs; Hugh J M Brady; Lei Yin
Journal:  J Biol Chem       Date:  2013-01-02       Impact factor: 5.157

6.  Cobalt chloride decreases fibroblast growth factor-21 expression dependent on oxidative stress but not hypoxia-inducible factor in Caco-2 cells.

Authors:  Yanlong Liu; Chunhong Wang; Yuhua Wang; Zhenhua Ma; Jian Xiao; Craig McClain; Xiaokun Li; Wenke Feng
Journal:  Toxicol Appl Pharmacol       Date:  2012-08-10       Impact factor: 4.219

7.  A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.

Authors:  Katrina Nicholes; Susan Guillet; Elizabeth Tomlinson; Kenneth Hillan; Barbara Wright; Gretchen D Frantz; Thinh A Pham; Lisa Dillard-Telm; Siao Ping Tsai; Jean-Philippe Stephan; Jeremy Stinson; Timothy Stewart; Dorothy M French
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

8.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

Review 9.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

Authors:  Hashem B El-Serag; Howard Hampel; Fariba Javadi
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

10.  Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.

Authors:  Jia Xiao; Chi Tat Ho; Emily C Liong; Amin A Nanji; Tung Ming Leung; Thomas Yue Huen Lau; Man Lung Fung; George L Tipoe
Journal:  Eur J Nutr       Date:  2013-03-21       Impact factor: 5.614

View more
  15 in total

Review 1.  Fibroblast growth factor 21: a regulator of metabolic disease and health span.

Authors:  Ting Xie; Po Sing Leung
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-05-30       Impact factor: 4.310

2.  Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.

Authors:  Xingkai Liu; Ping Zhang; Robert C Martin; Guozhen Cui; Guangyi Wang; Yi Tan; Lu Cai; Guoyue Lv; Yan Li
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

Review 3.  FGF21 in obesity and cancer: New insights.

Authors:  Weiqin Lu; Xiaokun Li; Yongde Luo
Journal:  Cancer Lett       Date:  2020-11-29       Impact factor: 8.679

4.  The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis.

Authors:  Xiao Zhang; Yongxia Qiao; Qi Wu; Yan Chen; Shaowu Zou; Xiangfan Liu; Guoqing Zhu; Yinghui Zhao; Yuxin Chen; Yongchun Yu; Qiuhui Pan; Jiayi Wang; Fenyong Sun
Journal:  Nat Commun       Date:  2017-05-05       Impact factor: 14.919

5.  Prevention of Streptozotocin-Induced Diabetic Nephropathy by MG132: Possible Roles of Nrf2 and IκB.

Authors:  Lili Kong; Yangwei Wang; Manyu Luo; Yi Tan; Wenpeng Cui; Lining Miao
Journal:  Oxid Med Cell Longev       Date:  2017-03-08       Impact factor: 6.543

6.  Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases.

Authors:  Liang Wu; Qingchun Pan; Guangyu Wu; Lingling Qian; Jing Zhang; Lei Zhang; Qichen Fang; Guoqing Zang; Yudong Wang; George Lau; Huating Li; Weiping Jia
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

7.  Fibroblast Growth Factor 21 Attenuates Diabetes-Induced Renal Fibrosis by Negatively Regulating TGF-β-p53-Smad2/3-Mediated Epithelial-to-Mesenchymal Transition via Activation of AKT.

Authors:  Sundong Lin; Lechu Yu; Yongqing Ni; Lulu He; Xiaolu Weng; Xuemian Lu; Chi Zhang
Journal:  Diabetes Metab J       Date:  2019-10-28       Impact factor: 5.376

8.  Overexpression of CTNND1 in hepatocellular carcinoma promotes carcinous characters through activation of Wnt/β-catenin signaling.

Authors:  Bo Tang; Fang Tang; Zhenran Wang; Guangying Qi; Xingsi Liang; Bo Li; Shengguang Yuan; Jie Liu; Shuiping Yu; Songqing He
Journal:  J Exp Clin Cancer Res       Date:  2016-05-18

9.  Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet.

Authors:  Garima Singhal; Gaurav Kumar; Suzanne Chan; Ffolliott M Fisher; Yong Ma; Hilde G Vardeh; Imad A Nasser; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Mol Metab       Date:  2018-03-08       Impact factor: 7.422

10.  Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling.

Authors:  Qianqian Zheng; Robert C Martin; Xiaoju Shi; Harshul Pandit; Youxi Yu; Xingkai Liu; Wei Guo; Min Tan; Ou Bai; Xin Meng; Yan Li
Journal:  Theranostics       Date:  2020-08-07       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.